Artificial Intelligence in Pre-clinical Drug Development for AD/ADRD (R01)

This grant invites applications that propose to apply existing or newly developed artificial intelligence (AI) and machine learning (ML) methods to various aspects of drug discovery and preclinical drug development to accelerate the identification, optimization, and selection of preclinical drug candidates for the treatment and prevention of Alzheimer’s disease (AD) and AD-related dementias (ADRD) and increase their likelihood of success during clinical drug development. Additionally, this grant aims to support the creation of advanced open-source analytical tools that will be made available to researchers in academia and biotech/pharma for more effective prosecution of AD/ADRD drug discovery campaigns for novel targets.

Funding: $1,000,000 per year

Duration: 5 years

Research Authority due date: 1.1.25

LOI (encouraged) due date: 13.1.25

Full application due date: 13.2.25